Drug Pricing Takes Over User Fee Hearing – And That Might Be Good News For Industry

Innovator companies are not generally happy when congressional committees focus on the cost of prescription drugs, particularly in hearings supposedly focused on other subjects. But when a Senate committee discussing the US FDA user fee reauthorization process devotes considerable time to the theme of pricing, it probably isn’t such a bad thing.